October 20, 2021
Technology

InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CD20xCD3 Bispecific Antibody CM355 | Antibodies

InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CD20xCD3 Bispecific Antibody CM355

BEIJING, China I September 17, 2021 I InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the Investigational New Drug (IND) of CM355, a CD20xCD3 bispecific antibody developed by a joint venture between the two companies called Tiannuojiancheng Pharma, has been cleared by the China’s National Medical Products Administration (NMPA).

CM355 binds to CD20 on the tumor cells and CD3 on the T cells, redirects and activates T cells to eradicate tumor cells through T-cell Directed Cellular Cytotoxicity (TDCC) in the treatment of CD20+ B-cell malignancies.

Non-Hodgkin lymphomas are the main type of CD20+…

Read full article here: pipelinereview.com